FDA approves leading next-generation diabetes wearable

Dexcom G7 app screen on apple iPhone. (Courtesy of Dexcom)

PROVIDENCE, R.I. (WLNE) — Dexcom’s next-generation G7 continuous glocuose monitoring system (GMS) was approved by the Food and Drug Administration last week for people 2 and older with Type 1 and Type 2 diabetes.

Since 1999, Dexcom has developed innovative continuous glucose monitoring (CGM) solutions to help people around the world to better manage diabetes.

The company announced their newest GMS on Dec. 8, saying that with diabetes on the rise, it’s more important than ever that people have access to simple, accurate, affordable technology.

According to the Centers for Disease Control and Prevention, 1 in 10 Americans are living with diabetes today, and another 1 in 5 people are living without diagnoses.

Dexcom said their new product will make diabetes management powerfully simple with new features, including a 60% smaller, all-in-one applicator and wearable and connectivity to automated insulin delivery systems and other digital app.

The G7 glucose monitoring system will be launching widely in early 2023.

For the latest information on the G7’s commercial availability, the company said to make sure you’re on Dexcom G6 and visit their webpage.

Categories: News